Nausea evaluation

The nurse always listens, evaluates, and reports any complaints die patient may have certain complaints may be an early sign of an adverse drug reaction. The nurse should report all changes in die patient s condition and any new problems that occur (eg, nausea or diarrhea) as soon as possible. It is tiien up to the primary health care provider to decide if tiiese changes or... 

Outline a monitoring plan to evaluate the treatment outcomes for nausea and vomiting. 

Evaluate potential side effects of therapy, including nausea, drowsiness, sleep attacks, and headaches for the DA agents. 

Evaluate patients taking allopurinol for development of rash, nausea, or new fever. These symptoms usually appear within the first 3 months of therapy but can occur anytime. 

TMP-SMX Nausea/vomiting Myelosuppression monitor CBC Hepatic abnormalities monitor LFTs Rash including severe reactions such as Stevens-Johnson syndrome Inhibitor of CYP2C9 evaluate for potential drug-drug interactions such as warfarin... 

Overall survival is affected by the success of the initial surgery to debulk the tumor to less than 1 cm of disease and response to first-line chemotherapy. The CA-125 level should be monitored with each cycle, and at least a 50% reduction in CA-125 after four cycles of taxane/platinum chemotherapy is related to an improved prognosis. Patients who achieve a complete response should have follow-up examinations every 3 months, including CA-125 determination, physical examination, pelvic examination, and appropriate diagnostic scans (e.g., CT scan, MRI, or PET scan) and should be evaluated for the detection of disease. Evaluate patients for resolution of any residual chemotherapy-related side effects, including neuropathies, nephrotoxicity, ototoxicity, myelosuppression, and nausea/vomiting. 

The effect of orlistat in adolescent patients has been evaluated recently. In a group of 12- to 16-year-old individuals, orlistat (120 mg three times daily) in combination with diet, exercise, and behavior modification exhibited minimal weight increase after 1 year (0.53 kg) compared with placebo-treated patients (3.14 kg). Common adverse reactions observed were fatty or oily stools, oily spotting, oily evacuation, or abdominal pain and/or flatulence with bowel movements. Soft stools, nausea, increased defecation, and fecal incontinence also were noted. Orlistat may be better suited for prevention of weight gain in tolerant adolescents, but more studies are warranted before providing a solid recommendation.36... 

An evaluation of the rifaximin tolerability profile observed in almost 1,000 patients from 30 clinical trials was unable to identify a definite pattern of intolerance [33]. Very few adverse events have been reported during short-tem treatment with the drug, the most frequently reported being gastrointestinal in nature (e.g. flatulence, nausea, abdominal pain and vomiting). It is worthwhile to emphasize that the detection of GI adverse reactions could have been difficult in rifaximin trials since the symptoms of the underlying diseases were often similar to the GI complaints observed after drug treatment. 

---